Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 241

1.

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.

Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Möller I, Schwamborn M, Sucker A, Hillen U, Badenas C, Malvehy J, Zimmer L, Scherag A, Puig S, Schadendorf D.

J Natl Cancer Inst. 2014 Sep 13;106(9). pii: dju246. doi: 10.1093/jnci/dju246. Print 2014 Sep.

2.

Analysis of SDHD promoter mutations in various types of melanoma.

Scholz SL, Horn S, Murali R, Möller I, Sucker A, Sondermann W, Stiller M, Schilling B, Livingstone E, Zimmer L, Reis H, Metz CH, Zeschnigk M, Paschen A, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG.

Oncotarget. 2015 Sep 22;6(28):25868-82. doi: 10.18632/oncotarget.4665.

3.

TERT promoter mutation is uncommon in acral lentiginous melanoma.

Liau JY, Tsai JH, Jeng YM, Chu CY, Kuo KT, Liang CW.

J Cutan Pathol. 2014 Jun;41(6):504-8. doi: 10.1111/cup.12323. Epub 2014 Apr 2.

PMID:
24588324
4.

Melanomas of unknown primary frequently harbor TERT-promoter mutations.

Egberts F, Krüger S, Behrens HM, Bergner I, Papaspyrou G, Werner JA, Alkatout I, Haag J, Hauschild A, Röcken C.

Melanoma Res. 2014 Apr;24(2):131-6. doi: 10.1097/CMR.0000000000000048.

PMID:
24463461
5.

TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.

Griewank KG, Murali R, Schilling B, Schimming T, Möller I, Moll I, Schwamborn M, Sucker A, Zimmer L, Schadendorf D, Hillen U.

PLoS One. 2013 Nov 18;8(11):e80354. doi: 10.1371/journal.pone.0080354. eCollection 2013.

6.

Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.

Vazquez Vde L, Vicente AL, Carloni A, Berardinelli G, Soares P, Scapulatempo C, Martinho O, Reis RM.

Melanoma Res. 2016 Apr;26(2):93-9. doi: 10.1097/CMR.0000000000000222.

PMID:
26709572
7.

Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.

Ofner R, Ritter C, Heidenreich B, Kumar R, Ugurel S, Schrama D, Becker JC.

J Cancer Res Clin Oncol. 2017 Apr;143(4):613-617. doi: 10.1007/s00432-016-2322-1. Epub 2016 Dec 18.

PMID:
27990595
8.

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases.

Bai X, Kong Y, Chi Z, Sheng X, Cui C, Wang X, Mao L, Tang B, Li S, Lian B, Yan X, Zhou L, Dai J, Guo J, Si L.

Clin Cancer Res. 2017 Oct 15;23(20):6120-6127. doi: 10.1158/1078-0432.CCR-17-0980. Epub 2017 Jul 18.

9.

Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.

Macerola E, Loggini B, Giannini R, Garavello G, Giordano M, Proietti A, Niccoli C, Basolo F, Fontanini G.

Virchows Arch. 2015 Aug;467(2):177-84. doi: 10.1007/s00428-015-1784-x. Epub 2015 Jun 9.

PMID:
26055532
10.

TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation.

Pópulo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, Pardal J, Azevedo F, Honavar M, Guimarães I, Manuel Lopes J, Sobrinho-Simões M, Soares P.

J Invest Dermatol. 2014 Aug;134(8):2251-2257. doi: 10.1038/jid.2014.163. Epub 2014 Apr 1.

11.

TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.

Griewank KG, Murali R, Schilling B, Scholz S, Sucker A, Song M, Süsskind D, Grabellus F, Zimmer L, Hillen U, Steuhl KP, Schadendorf D, Westekemper H, Zeschnigk M.

Br J Cancer. 2013 Jul 23;109(2):497-501. doi: 10.1038/bjc.2013.312. Epub 2013 Jun 25.

12.

Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.

Egberts F, Bergner I, Krüger S, Haag J, Behrens HM, Hauschild A, Röcken C.

Ann Oncol. 2014 Jan;25(1):246-50. doi: 10.1093/annonc/mdt411. Epub 2013 Nov 24.

PMID:
24276025
13.

TERT promoter mutations in melanoma survival.

Nagore E, Heidenreich B, Rachakonda S, Garcia-Casado Z, Requena C, Soriano V, Frank C, Traves V, Quecedo E, Sanjuan-Gimenez J, Hemminki K, Landi MT, Kumar R.

Int J Cancer. 2016 Jul 1;139(1):75-84. doi: 10.1002/ijc.30042. Epub 2016 Mar 2.

14.

Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients.

Roh MR, Park KH, Chung KY, Shin SJ, Rha SY, Tsao H.

Am J Cancer Res. 2017 Jan 1;7(1):134-138. eCollection 2017.

15.

TERT promoter mutation subtypes and survival in stage I and II melanoma patients.

Andrés-Lencina JJ, Rachakonda S, García-Casado Z, Srinivas N, Skorokhod A, Requena C, Soriano V, Kumar R, Nagore E.

Int J Cancer. 2019 Mar 1;144(5):1027-1036. doi: 10.1002/ijc.31780. Epub 2018 Oct 4.

PMID:
30070694
16.

Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.

Thomas NE, Edmiston SN, Tsai YS, Parker JS, Googe PB, Busam KJ, Scott GA, Zedek DC, Parrish EA, Hao H, Slater NA, Pearlstein MV, Frank JS, Kuan PF, Ollila DW, Conway K.

Am J Dermatopathol. 2019 Apr;41(4):264-272. doi: 10.1097/DAD.0000000000001259.

PMID:
30211730
17.

Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.

Wu S, Kuo H, Li WQ, Canales AL, Han J, Qureshi AA.

Cancer Causes Control. 2014 Oct;25(10):1379-86. doi: 10.1007/s10552-014-0443-x. Epub 2014 Jul 22.

18.

The role of BRAF mutations in primary melanoma growth rate and survival.

Mar VJ, Liu W, Devitt B, Wong SQ, Dobrovic A, McArthur GA, Wolfe R, Kelly JW.

Br J Dermatol. 2015 Jul;173(1):76-82. doi: 10.1111/bjd.13756. Epub 2015 Jun 13.

PMID:
25752325
19.

Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma.

Hugdahl E, Kalvenes MB, Mannelqvist M, Ladstein RG, Akslen LA.

Br J Cancer. 2018 Jan;118(1):98-105. doi: 10.1038/bjc.2017.384. Epub 2017 Nov 9.

20.

Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.

Koopmans AE, Ober K, Dubbink HJ, Paridaens D, Naus NC, Belunek S, Krist B, Post E, Zwarthoff EC, de Klein A, Verdijk RM; Rotterdam Ocular Melanoma Study Group.

Invest Ophthalmol Vis Sci. 2014 Aug 26;55(9):6024-30. doi: 10.1167/iovs.14-14901.

PMID:
25159205

Supplemental Content

Support Center